Terbinafine: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| Line 52: | Line 52: | ||
==See Also== | ==See Also== | ||
*[[Antifungals]] | *[[Antifungals]] | ||
*[[Fungal infections]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | [[Category:ID]] | ||
Latest revision as of 03:31, 8 March 2021
Administration
- Type: Antifungal
- Dosage Forms:
- Routes of Administration: Oral, topical
- Common Trade Names: Lamisil
Adult Dosing
- 250-500mg PO 1-2 times per day
- Apply topically 1-2 times per day
Pediatric Dosing
- >12yo, topical: apply 1-2 times per day
- >4yo, oral
- <25kg: 125mg PO daily
- 25-35kg: 187.5mg PO daily
- >25kg: 250mg PO daily
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: contraindicated in hepatic impairment
Contraindications
- Allergy to class/drug
- Chronic or active liver disease
Adverse Reactions
Serious
- SJS/TEN
- Acute generalized exanthematous pustulosis
- Systemic or cutaneous lupus
- Neutropenia
- Liver failure
- Hearing loss
Common
- Nausea, vomiting, diarrhea, indigestion
- Rash
- Elevated LFTs
- Headache
- Cough, fever, URI symptoms
Pharmacology
- Half-life: 22-26h
- Metabolism: Hepatic CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19
- Excretion: Mostly renal
Mechanism of Action
- Inhibits ergosterol in fungal cell membrane